Stephanie Hsiao, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hsiao’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A141281 · Current
Licensed to practise in California · since 2016 · expires 2027-10-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$50,742
Medicare paid this office $50,742 for 109 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $21,613 | $106 |
| Critical care, first 30-74 minutes | 33 | $14,733 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,521 | $67 |
| Long return visit (40+ min) | 26 | $4,043 | $126 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,878 | $104 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $21,613 | $106 |
| Critical care, first 30-74 minutes | 33 | $14,733 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,521 | $67 |
| Long return visit (40+ min) | 26 | $4,043 | $126 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,878 | $104 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,224 | $94 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $838 | $44 |
Who their Medicare patients are
109 Original Medicare patients in 2024. Average age 70 · Under 65 29% · 85 and older 17% · Women 38% · Also on Medicaid 36% · Health risk score 3.84. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 75% · Chronic kidney disease 75% · Coronary heart disease 73% · Atrial fibrillation 64% · Diabetes 58% · Depression 34% · COPD 32% · Dementia 26% · Stroke 25% · Cancer 16%.
The office billed $296,906, Medicare allowed $65,102 and paid $50,742; for 475 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 109 | 475 | 70 | 3.84 | $296,906 | $50,742 |
| 2023 | 98 | 388 | 69 | 4.65 | $192,471 | $39,403 |
| 2022 | 35 | 151 | 65 | 3.16 | $55,782 | $13,581 |
| 2018 | 18 | 34 | 81 | 1.82 | $11,642 | $3,025 |
| 2017 | 12 | 18 | 80 | 3.37 | $7,572 | $1,978 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $17,678 | $106 |
| Critical care, first 30-74 minutes | 12 | $6,578 | $188 |
| Long return visit (40+ min) | 33 | $4,288 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,493 | $71 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,553 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,753 | $117 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,108 | $74 |
2022: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $8,631 | $92 |
| Long return visit (40+ min) | 12 | $1,586 | $132 |
2018: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,409 | $93 |
Drugs they prescribed that Part D paid
$59,630
Pharmacies billed $59,630 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
288 generic and 63 brand-name prescriptions · $59,630 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sirolimus | 31 | $9,303 | $300 |
| Envarsus Xr | 20 | $9,093 | $455 |
| Praluent | 11 | $5,138 | $467 |
| Tacrolimus | 23 | $2,714 | $118 |
| Mycophenolate Mofetil | 11 | $1,542 | $140 |
See all 10 drugs
| Sirolimus | 31 | $9,303 | $300 |
| Envarsus Xr | 20 | $9,093 | $455 |
| Praluent | 11 | $5,138 | $467 |
| Tacrolimus | 23 | $2,714 | $118 |
| Mycophenolate Mofetil | 11 | $1,542 | $140 |
| Pantoprazole | 15 | $313 | $21 |
| Rosuvastatin | 17 | $239 | $14 |
| Amlodipine Besylate | 22 | $117 | $5 |
| Lisinopril | 17 | $53 | $3 |
| Chlorthalidone | 13 | $35 | $3 |
Year by year
| 2024 | 351 | 77 | None | 18% | $59,630 |
| 2023 | 370 | 66 | 0% (0) | 13% | $80,419 |
| 2022 | 26 | 19 | 0% (0) | None | $5,148 |
| 2021 | 88 | 25 | None | 17% | $2,953 |
| 2020 | 145 | 51 | 0% (0) | 19% | $18,124 |
| 2019 | 145 | 53 | 0% (0) | None | $17,897 |
| 2018 | 112 | 34 | 0% (0) | 20% | $7,920 |
| 2017 | 41 | 15 | 0% (0) | None | $2,077 |
| 2016 | 11 | None | 0% (0) | None | $482 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Sirolimus | 35 | $28,989 | $828 |
| Everolimus | 13 | $10,978 | $844 |
| Envarsus Xr | 16 | $8,109 | $507 |
| Tacrolimus | 20 | $5,895 | $295 |
| Amlodipine Besylate | 34 | $602 | $18 |
| Rosuvastatin | 29 | $420 | $14 |
| Hydralazine | 14 | $375 | $27 |
| Levothyroxine | 18 | $204 | $11 |
| Chlorthalidone | 13 | $171 | $13 |
2020: 3 drugs
| Metoprolol | 21 | $630 | $30 |
| Atorvastatin | 15 | $242 | $16 |
| Furosemide | 14 | $71 | $5 |
2019: 6 drugs
| Brilinta | 11 | $5,675 | $516 |
| Eliquis | 11 | $4,272 | $388 |
| Metoprolol | 12 | $316 | $26 |
| Atorvastatin | 14 | $314 | $22 |
| Furosemide | 11 | $107 | $10 |
| Carvedilol | 11 | $98 | $9 |
Money from drug and device companies
$6,829 in 2025
| 2025 | 1 | 10 | $4,500 | $6,829 |
| 2024 | 1 | 3 | None | $160 |
| 2023 | 1 | 1 | None | $49 |
| 2022 | 1 | 9 | None | $1,562 |
| 2021 | 10 | 20 | None | $739 |
| 2020 | 8 | 38 | None | $817 |
| 2019 | 11 | 86 | None | $2,195 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CVRx | Barostim Neo System | $6,829 | 10 payments
|
See all 10 published payments
| CVRx | Consulting · 2025-06-06 | Barostim Neo System | $4,500 |
| CVRx | Travel · 2025-05-09 | Barostim Neo System | $430 |
| CVRx | Meals · 2025-05-09 | Barostim Neo System | $31 |
| CVRx | Meals · 2025-05-09 | Barostim Neo System | $78 |
| CVRx | Meals · 2025-05-09 | Barostim Neo System | $78 |
| CVRx | Meals · 2025-05-09 | Barostim Neo System | $102 |
| CVRx | Meals · 2025-05-09 | Barostim Neo System | $292 |
| CVRx | Travel · 2025-04-08 | Barostim Neo System | $34 |
| CVRx | Travel · 2025-04-08 | Barostim Neo System | $565 |
| CVRx | Travel · 2025-01-08 | Barostim Neo System | $719 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $160
| Paragonix Technologies | None | $160 | 3 payments
|
2023: $49
| La Jolla Pharmaceutical | Giapreza | $49 | 1 payment
|
2022: $1,562
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $1,562 | 9 payments
|
2021: $739
| Boston Scientific | General Pain Management | $248 | 1 payment
|
| Abbott Laboratories | Ensite Precision Cardiac Mapping System | $165 | 2 payments
|
| Pfizer | Eliquis | $69 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $48 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $47 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $47 | 3 payments
|
| Chiesi USA | Kengreal | $37 | 3 payments
|
| Amgen | Repatha | $33 | 2 payments
|
| Esperion Therapeutics | Nexletol | $27 | 1 payment
|
| Lundbeck | Northera | $20 | 1 payment
|
2020: $817
| Amgen | Repatha | $176 | 8 payments
|
| Chiesi USA | Cleviprex 50mg/100ml | $155 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $127 | 4 payments
|
| Pfizer | Eliquis | $118 | 6 payments
|
| Lundbeck | Northera | $94 | 4 payments
|
| Abbott Laboratories | Perclose Proglide Suture Mediated Closure System | $77 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $36 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $34 | 2 payments
|
2019: $2,195
| Amgen | Repatha | $621 | 22 payments
|
| Abbott Laboratories | Mitra Clip System | $254 | 3 payments
|
| Boston Scientific | Emblem | $208 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $207 | 11 payments
|
| Pfizer | Eliquis | $174 | 8 payments
|
| Regeneron Healthcare Solutions | Praluent | $170 | 9 payments
|
| Medtronic Vascular | Azure | $164 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $141 | 8 payments
|
| Sanofi-Aventis U.S. | Praluent | $109 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $92 | 5 payments
|
| Alnylam Pharmaceuticals | Onpattro | $55 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1245650456
- Licence
- CA A141281California A141281: Current · expires 2027-10-31
- Trained
- University of California, San Francisco School of Medicine, 2014
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-04-27
- NPI last updated
- 2025-03-26
- NPI record certified
- 2025-03-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2351 Clay St, San Francisco, CA, 94115